Hansa Medical announces prospectus
The information in this press release is not directed at persons located in Australia, Canada, Hong Kong, Japan, New Zealand, the Republic of Korea, Singapore, South Africa, Switzerland, the United States or any other country where the offer or sale of subscription rights, interim shares or new shares is not permitted. The information may not be published or distributed, directly or indirectly, in or into, any of the aforementioned countries or any other country where such action is wholly or partially subject to legal restrictions or where such action would require additional prospectuses, other offer documentation, registrations or other actions in addition to what follows from Swedish law. Nor may the information be forwarded, reproduced or disclosed in such a manner that contravenes such restrictions or gives cause to such requirements. Failure to comply with these instructions may result in a violation of the United States Securities Act of 1933, as amended (“Securities Act”) or laws applicable in other jurisdictions.
The information in this press release does not contain or constitute an invitation or an offer to acquire, sell, subscribe for or otherwise trade in shares, subscription rights or other securities in Hansa Medical AB. No subscription rights, interim shares or new shares will be registered under the Securities Act or in accordance with any other rules or regulations in any other country than Sweden and may not be transferred or offered for sale in the United States or any country where such transfer or offer may be prohibited, or to persons resident in any such country or on account of such persons, other than pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act or similar legislation in another country, respectively.
The Board of Hansa Medical AB (publ) has prepared a prospectus due to the listing. The prospectus has today, October 27, 2015, been approved by and registered with the Swedish Financial Supervisory Authority (Sw. Finansinspektionen) in accordance with the Financial Instruments Trading Act (Sw. lagen (1991:980) om handel med finansiella instrument).
The prospectus is available on Hansa Medical’s website (www.hansamedical.com) and will be available on the Swedish Financial Supervisory Authority’s website (www.fi.se/Register/Prospektregistret).
The prospectus contains revised financial statements of historical financial information regarding the financial years of 2012, 2013 and 2014, which have been audited by the company’s auditor.
The first day of trading is planned to fall on November 2, 2015.
The information in this press release was released for public disclosure on October 27, 2015 at 08.00 CET.
For further information, please contact:
Hansa Medical AB
Göran Arvidson, CEO
Mobile: +46 70-390 85 30
About Hansa Medical
Hansa Medical is a biopharmaceutical company focused on novel immunomodulatory enzymes. Lead project IdeS is an antibody-degrading enzyme in clinical development, with potential use in transplantation and rare autoimmune diseases. Other projects include HBP (a market introduced diagnostic marker for severe sepsis) and EndoS (an antibody-modulating bacterial enzyme in pre-clinical development). The company is based in Lund, Sweden. Hansa Medical's share (HMED) is listed on First North Premier in Stockholm with Remium Nordic AB as Certified Adviser.